Press Releases

The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and the Kidney Cancer Association (KCA) are proud to announce a new joint Request for Applications (RFA) to advance the early detection and diagnosis of kidney cancer. This collaborative funding opportunity supports clinical validation studies and early-phase interventional trials (Phase I or II) that leverage innovative imaging technologies, biomarkers, or monitoring…

During Kidney Cancer Awareness Month, the Kidney Cancer Association encourages everyone to #OrangeUp and honor those impacted by this disease.   In the US, over 600,000 people live with kidney cancer and about 81,000 new cases will be diagnosed in 2025.   However, in the last decade, over a dozen new treatments for kidney cancer have been approved the research community continues…

The Kidney Cancer Association (KCA) will partner with Topline Bio, LLC for a new era of digital education and storytelling with and for healthcare professionals treating kidney cancer as well as patients and families impacted by the disease. This partnership solidifies our ability to create the sort of content that can revolutionize communication in our space by bringing easily digestible…

The Kidney Cancer Association (KCA) awarded five grants to investigators pursuing high-impact kidney cancer research across a variety of focus areas through its annual KCA Award Program. Each $75,000 award supports early- to mid-career investigators whose projects align with topics that require greater attention and understanding from researchers, doctors, and patients. In total, the KCA distributed $375,000 in research funds.…

The Metastatic Brain Tumor Collaborative (MBTC), created by the American Brain Tumor Association (ABTA), announced a request for applications for one-year, $50,000 research grants. Faculty – including early-career faculty – are encouraged to apply.  Applicants should propose high-risk, high-impact research projects that will improve the understanding of brain metastasis and have the potential to change current diagnostic or treatment paradigms…

NEW YORK, NY and HOUSTON, TX — The Cancer Research Institute (CRI) is proud to announce a new collaboration with the Kidney Cancer Association (KCA) to fund a CRI  Clinic & Laboratory Integration Program (CLIP) investigator specifically for immunologists and cancer researchers who are pursuing innovative kidney cancer research. CLIP grants are designed to support preclinical and translational research aimed at optimizing cancer immunotherapy…

The Kidney Cancer Association (KCA) is collaborating with Tempus to support a postdoctoral research fellowship focused on accelerating kidney cancer research through artificial intelligence and precision medicine. Applications for this fellowship are open now. The selected postdoctoral fellow will be hired as a Tempus employee and receive funding to complete a research project over 2 years. The fellow will benefit…

The partnership will empower patients with greater control over their health data and accelerate the discovery and approval of new treatments for kidney cancer. The Kidney Cancer Association (KCA) has partnered with xCures, the AI-driven medical record aggregator and research company, to offer kidney cancer patients the opportunity to contribute to research through clinical trials. Together, KCA and xCures will…

The Ferrell Foundation, an Austin, Texas-based cancer support non-profit, donated $10,000 to support the Kidney Cancer Association’s (KCA) Patient Assistance Fund (PAF). https://www.www.kidneycancer.org/stories/spotlight-john-ferrell/ The PAF offers patients and families no-strings attached grants to relieve the financial burdens that accompany a kidney cancer diagnosis including treatment costs, transportation, and lodging. As the most common query among those who contact the KCA’s…

The Kidney Cancer Association (KCA) and the Chromophobe and Oncocytic Tumor Alliance (COA) will co-sponsor a 2024 research award specifically for researchers investigating distinguishing biological hallmarks of and treatments for chromophobe renal cell carcinoma (chRCC), a rare type of kidney cancer. This Chromophobe RCC Focus Award will provide $75,000 for one year to the selected researcher. It is one of…